Publication: HLA Alleles Influence the Clinical Signature of Amoxicillin-Clavulanate Hepatotoxicity.
| dc.contributor.author | Stephens, Camilla | |
| dc.contributor.author | López-Nevot, Miguel-Ángel | |
| dc.contributor.author | Ruiz-Cabello, Francisco | |
| dc.contributor.author | Ulzurrun, Eugenia | |
| dc.contributor.author | Soriano, Germán | |
| dc.contributor.author | Romero-Gómez, Manuel | |
| dc.contributor.author | Moreno-Casares, Antonia | |
| dc.contributor.author | Lucena, M Isabel | |
| dc.contributor.author | Andrade, Raul J | |
| dc.contributor.authoraffiliation | [Stephens,C; Ulzurrun,E; Lucena,MI; Andrade,RJ] Unidad de Gestión Clínica de Enfermedades Digestivas, Servicio de Farmacología Clínica, Hospital Universitario Virgen de la Victoria. Instituto de Investigación Biomédica de Málaga-IBIMA, Universidad de Málaga, Spain. [López-Nevot,MA; Ruiz-Cabello,F; Moreno-Casares,A] Departamento de Bioquímica y Biología Molecular III/Inmunología, Hospital Universitario Virgen de las Nieves, Universidad de Granada, Spain. [Soriano,G] Servicio de Gastroenterología, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. [Romero-Gómez,M] Unidad de Gestión Clínica de Enfermedades Digestivas, Hospital Universitario de Valme, Universidad de Sevilla, Andalucía Tech, Sevilla, Spain. [Stephens,C; Ulzurrun,E; Soriano,G; Romero-Gómez,M; Lucena,MI; Andrade,RJ] Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain. [Ruiz-Cabello,F] Red Genómica del Cáncer, Madrid, Spain. | |
| dc.date.accessioned | 2024-01-15T18:17:02Z | |
| dc.date.available | 2024-01-15T18:17:02Z | |
| dc.date.issued | 2013-07 | |
| dc.description.abstract | BACKGROUND AND AIM: The genotype-phenotype interaction in drug-induced liver injury (DILI) is a subject of growing interest. Previous studies have linked amoxicillin-clavulanate (AC) hepatotoxicity susceptibility to specific HLA alleles. In this study we aimed to examine potential associations between HLA class I and II alleles and AC DILI with regards to phenotypic characteristics, severity and time to onset in Spanish AC hepatotoxicity cases. METHODS: High resolution genotyping of HLA loci A, B, C, DRB1 and DQB1 was performed in 75 AC DILI cases and 885 controls. RESULTS: The distributions of class I alleles A*3002 (P/Pc = 2.6E-6/5E-5, OR 6.7) and B*1801 (P/Pc = 0.008/0.22, OR 2.9) were more frequently found in hepatocellular injury cases compared to controls. In addition, the presence of the class II allele combination DRB1*1501-DQB1*0602 (P/Pc = 5.1E-4/0.014, OR 3.0) was significantly increased in cholestatic/mixed cases. The A*3002 and/or B*1801 carriers were found to be younger (54 vs 65 years, P = 0.019) and were more frequently hospitalized than the DRB1*1501-DQB1*0602 carriers. No additional alleles outside those associated with liver injury patterns were found to affect potential severity as measured by Hy's Law criteria. The phenotype frequencies of B*1801 (P/Pc = 0.015/0.42, OR 5.2) and DRB1*0301-DQB1*0201 (P/Pc = 0.0026/0.07, OR 15) were increased in AC DILI cases with delayed onset compared to those corresponding to patients without delayed onset, while the opposite applied to DRB1*1302-DQB1*0604 (P/Pc = 0.005/0.13, OR 0.07). CONCLUSIONS: HLA class I and II alleles influence the AC DILI signature with regards to phenotypic expression, latency presentation and severity in Spanish patients. | |
| dc.description.sponsorship | This study was supported by the research grant Proyecto Excelencia P10-CTS-6470 and by the Agencia Española del Medicamento. CIBERehd and Red Genómica del Cancer are funded by Instituto de Salud Carlos III | |
| dc.identifier.doi | 10.1371/journal.pone.0068111 | |
| dc.identifier.e-issn | 1932-6203 | es_ES |
| dc.identifier.journal | PloS One | es_ES |
| dc.identifier.other | http://hdl.handle.net/10668/1272 | |
| dc.identifier.pubmedID | 23874514 | es_ES |
| dc.identifier.uri | http://hdl.handle.net/20.500.12105/17053 | |
| dc.language.iso | eng | |
| dc.publisher | Public Library of Science (PLOS) | |
| dc.relation.publisherversion | http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0068111 | es |
| dc.rights.accessRights | open access | es_ES |
| dc.rights.license | Attribution 4.0 International | * |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | * |
| dc.subject | Combinación Amoxicilina-Clavulanato de Potasio | |
| dc.subject | Enfermedad Hepática Inducida por Drogas | |
| dc.subject | Predisposición Genética a la Enfermedad | |
| dc.subject | Haplotipos | |
| dc.subject | Fenotipo | |
| dc.subject | Inmunidad Adaptativa | |
| dc.subject | Antibacterianos | |
| dc.subject | Genes Clase I del Complejo de Histocompatibilidad (MHC) | |
| dc.subject | Genes Clase II del Complejo de Histocompatibilidad (MHC) | |
| dc.subject | Antígenos HLA-A | |
| dc.subject | Antígenos HLA-DQ | |
| dc.subject | Antígenos HLA-DR | |
| dc.subject | Cadenas beta de HLA-DR | |
| dc.subject | Factores de riesgo | |
| dc.subject | España | |
| dc.subject.mesh | Amoxicillin-Potassium Clavulanate Combination | |
| dc.subject.mesh | Drug-Induced Liver Injury | |
| dc.subject.mesh | Genetic Predisposition to Disease | |
| dc.subject.mesh | Haplotypes | |
| dc.subject.mesh | Phenotype | |
| dc.subject.mesh | Adaptive Immunity | |
| dc.subject.mesh | Anti-Bacterial Agents | |
| dc.subject.mesh | Genes, MHC Class I | |
| dc.subject.mesh | Genes, MHC Class II | |
| dc.subject.mesh | HLA-A Antigens | |
| dc.subject.mesh | HLA-DQ Antigens | |
| dc.subject.mesh | HLA-DR Antigens | |
| dc.subject.mesh | HLA-DR beta-Chains | |
| dc.subject.mesh | Risk Factors | |
| dc.subject.mesh | Spain | |
| dc.title | HLA Alleles Influence the Clinical Signature of Amoxicillin-Clavulanate Hepatotoxicity. | |
| dc.type | research article | |
| dc.type.hasVersion | VoR | |
| dspace.entity.type | Publication | |
| relation.isPublisherOfPublication | a2759e3d-0d58-4e8a-9fcd-c6130ee333d1 | |
| relation.isPublisherOfPublication.latestForDiscovery | a2759e3d-0d58-4e8a-9fcd-c6130ee333d1 |


